| |
 |
|
Class Information
Number: 514/2
Name: Drug, bio-affecting and body treating compositions > Designated organic active ingredient containing (doai) > Peptide containing (e.g., protein, peptones, fibrinogen, etc.) doai
Description: Subject matter which contains a protein or its reaction product, e.g., peptides, peptones, fibrinogen, etc., wherein the protein molecule is not degraded to the constituent amino-acids.
Sub-classes under this class:
| Class Number |
Class Name |
Patents |
| 514/14 |
12 to 15 peptide repeating units in known peptide chain |
1,115 |
| 514/13 |
16 to 24 peptide repeating units in known peptide chain |
1,152 |
| 514/19 |
2 peptide repeating units in known peptide chain |
1,319 |
| 514/12 |
25 or more peptide repeating units in known peptide chain structure |
5,597 |
| 514/18 |
3 or 4 peptide repeating units in known peptide chain |
1,596 |
| 514/17 |
5 or 6 peptide repeating units in known peptide chain |
1,071 |
| 514/16 |
7 or 8 peptide repeating units in known peptide chain |
1,047 |
| 514/15 |
9 to 11 peptide repeating units in known peptide chain |
1,375 |
| 514/9 |
Cyclopeptides |
698 |
| 514/8 |
Glycoprotein (carbohydrate containing) |
2,033 |
| 514/6 |
Heavy metal containing (e.g., hemoglobin, etc.) |
451 |
| 514/3 |
Insulin or derivative |
608 |
| 514/5 |
Iodine containing |
42 |
| 514/7 |
Phosphorus containing |
196 |
| 514/21 |
Produced by or extracted from animal tissue |
2,378 |
Patents under this class:
| Patent Number |
Title Of Patent |
Date Issued |
| 7435718 |
CXCR4 antagonist treatment of hematopoietic cells |
Oct. 14, 2008 |
| 7435717 |
Pharmaceutical formulations, methods, and dosing regimens for the treatment and prevention of acute coronary syndromes |
Oct. 14, 2008 |
| 7435716 |
Compounds pharmaceutical compositions and methods for treatment of bacteremia and/or septicemia |
Oct. 14, 2008 |
| 7435421 |
Derivatives of choline binding proteins for vaccines |
Oct. 14, 2008 |
| 7435420 |
Dipeptidyl peptidase IV inhibitors for the treatment of anxiety |
Oct. 14, 2008 |
| 7435419 |
Methods of diagnosing and treating pre-eclampsia or eclampsia |
Oct. 14, 2008 |
| 7435418 |
Receptor for B. anthracis toxin |
Oct. 14, 2008 |
| 7435408 |
Porous particles comprising excipients for deep lung delivery |
Oct. 14, 2008 |
| 7432301 |
Use of S-nitrosothiol signaling to treat disordered control of breathing |
Oct. 7, 2008 |
| 7432251 |
Methods of treating neurological diseases by regulating migration of neuroblasts in the adult nervous system with tenascin-R |
Oct. 7, 2008 |
| 7432241 |
Device for treating diabetes and methods thereof |
Oct. 7, 2008 |
| 7432240 |
Fumaric acid amides |
Oct. 7, 2008 |
| 7432239 |
Polyoxyalkylene compound and method for making |
Oct. 7, 2008 |
| 7432238 |
Human Kunitz-type inhibitor with enhanced antifibrinolytic activity |
Oct. 7, 2008 |
| 7432237 |
Methods of treating asthma by administering interleukin-17 receptor |
Oct. 7, 2008 |
| 7432236 |
Vasostatin as marrow protectant |
Oct. 7, 2008 |
| 7431936 |
Proteins involved in cytoadhesion of plasmodium falciparum ring-stage-infected erythrocytes, antibodies which bind to the proteins, and methods for detecting infection, stage of infection and |
Oct. 7, 2008 |
| 7431935 |
Proteins within the type E botulinum neurotoxin complex |
Oct. 7, 2008 |
| 7429563 |
Peptide carrier for drug delivery |
Sep. 30, 2008 |
| 7429562 |
Cyclosporin analog formulations |
Sep. 30, 2008 |
| 7429561 |
Method for stimulating cell growth using sponge protein hydrolysates |
Sep. 30, 2008 |
| 7429560 |
Ketoamide inhibitors in chronic nerve disease |
Sep. 30, 2008 |
| 7429559 |
Controlled release composition and method of producing the same |
Sep. 30, 2008 |
| 7429483 |
Use of nerve growth factor for the storage, culture or treatment of cornea |
Sep. 30, 2008 |
| 7429388 |
Vaccine for nontypeable Haemophilus influenzae infection |
Sep. 30, 2008 |
| 7429384 |
Chimeric antagonist anth1 |
Sep. 30, 2008 |
| 7427607 |
Drug administration method |
Sep. 23, 2008 |
| 7427602 |
Sustained DNA delivery from structural matrices |
Sep. 23, 2008 |
| 7427597 |
Method of treating brain tissue damages |
Sep. 23, 2008 |
| 7427593 |
Methods of making triacylglycerol using phospholipid:Diacylglycerol acyltransferase |
Sep. 23, 2008 |
| 7427592 |
Factor VII or VIIa - like molecules |
Sep. 23, 2008 |
| 7427591 |
Suppression of immune response via inhibition of cathepsin S |
Sep. 23, 2008 |
| 7427590 |
Neurothrophic components of the ADNF I complex |
Sep. 23, 2008 |
| 7427589 |
Use of cytokine inhibitors |
Sep. 23, 2008 |
| 7427503 |
Method for transferring material in a cell system |
Sep. 23, 2008 |
| 7427408 |
Quorum sensing and biofilm formation |
Sep. 23, 2008 |
| 7427404 |
Pertussis toxin mutants, bordetella strains capable of producing such mutants and their use in the development of antipertussis vaccines |
Sep. 23, 2008 |
| 7427403 |
Methods for inhibiting lymphotoxin .beta. receptor signalling |
Sep. 23, 2008 |
| 7425549 |
Drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis |
Sep. 16, 2008 |
| 7425540 |
Method for modification of NMDA receptors through inhibition of Src |
Sep. 16, 2008 |
| 7425539 |
Factor IXa for the treatment of bleeding disorders |
Sep. 16, 2008 |
| 7425536 |
Feline hepatocyte growth factor |
Sep. 16, 2008 |
| 7425535 |
Therapeutic pore-forming peptides |
Sep. 16, 2008 |
| 7425534 |
Compositions and methods for modulating muscle cell and tissue contractility |
Sep. 16, 2008 |
| 7425533 |
Modified hirudin proteins and T-cell epitopes in hirudin |
Sep. 16, 2008 |
| 7425532 |
Use of alanyl aminopeptidase inhibitors and pharmaceutical compositions containing said inhibitors |
Sep. 16, 2008 |
| 7425531 |
Bone polypeptide-1 |
Sep. 16, 2008 |
| 7425530 |
Stereoselective preparation of cyclic L-amino acids |
Sep. 16, 2008 |
| 7425339 |
CD8alpha mutants |
Sep. 16, 2008 |
| 7425338 |
Clostridial toxin derivatives and methods for treating pain |
Sep. 16, 2008 |
|
|
|
